Literature DB >> 21989693

Immunologic alterations and the pathogenesis of organ failure in the ICU.

Steven M Opal1.   

Abstract

Rapid and marked alterations of innate and adaptive immunity typify the host response to systemic infection and acute inflammatory states. Immune dysfunction contributes to the development of organ failure in most patients with critical illness. The molecular mechanisms by which microbial pathogens and tissue injury activate myeloid cells and prime cellular and humoral immunity are increasingly understood. An early and effective immune response to microbial invasion is essential to mount an effective antimicrobial response. However, unchecked and nonresolving inflammation can induce diffuse vasodilation, increased capillary permeability, microvascular damage, coagulation activation, and organ dysfunction. Control of the inflammatory response to limit tissue damage, yet retain the antimicrobial responses in critically ill patients with severe infection, has been sought for decades. Anti-inflammatory approaches might be beneficial in some patients but detrimental in others. It is now clear that a state of sepsis-induced immune suppression can follow the immune activation phase of sepsis. In carefully selected patients, a better therapeutic strategy might be to provide immunoadjuvants to reconstitute immune function in intensive care unit (ICU) patients. Proresolving agents are also in development to terminate acute inflammatory reactions without immune suppression. This brief review summarizes the current understanding of the fundamental immune alterations in critical illness that lead to organ failure in critical illness. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989693     DOI: 10.1055/s-0031-1287865

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  12 in total

1.  Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study.

Authors:  Ildiko Toth; Andras Mikor; Tamas Leiner; Zsolt Molnar; Lajos Bogar; Tamas Szakmany
Journal:  J Anesth       Date:  2013-01-12       Impact factor: 2.078

2.  Hyporesponsiveness of natural killer cells and impaired inflammatory responses in critically ill patients.

Authors:  Minkyung Kim; Minjoo Kim; Hana Jeong; Jey Sook Chae; Young Sam Kim; Jae Gil Lee; Younsoo Cho; Jong Ho Lee
Journal:  BMC Immunol       Date:  2017-12-08       Impact factor: 3.615

3.  Early rehabilitation for the prevention of postintensive care syndrome in critically ill patients: a study protocol for a systematic review and meta-analysis.

Authors:  Yutaka Kondo; Ryota Fuke; Toru Hifumi; Junji Hatakeyama; Tetsuhiro Takei; Kazuma Yamakawa; Shigeaki Inoue; Osamu Nishida
Journal:  BMJ Open       Date:  2017-03-01       Impact factor: 2.692

4.  Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation.

Authors:  Elena G Novoselova; Sergey M Lunin; Olga V Glushkova; Maxim O Khrenov; Svetlana B Parfenyuk; Nadezhda M Zakharova; Evgeny E Fesenko
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

5.  Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy.

Authors:  Stefanie Prohaska; Andrea Schirner; Albina Bashota; Andreas Körner; Gunnar Blumenstock; Helene A Haeberle
Journal:  J Intensive Care       Date:  2018-02-26

6.  Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.

Authors:  Victoria L M Herrera; Allan J Walkey; Mai Q Nguyen; Christopher M Gromisch; Julie Z Mosaddhegi; Matthew S Gromisch; Bakr Jundi; Soeren Lukassen; Saskia Carstensen; Ridiane Denis; Anna C Belkina; Rebecca M Baron; Mayra Pinilla-Vera; Meike Muller; W Taylor Kimberly; Joshua N Goldstein; Irina Lehmann; Angela R Shih; Roland Eils; Bruce D Levy; Nelson Ruiz-Opazo
Journal:  Res Sq       Date:  2021-09-13

7.  Ventilator-associated Pneumonia caused by commensal oropharyngeal Flora; [corrected] a retrospective Analysis of a prospectively collected Database.

Authors:  Johannes B J Scholte; Johan I M van der Velde; Catharina F M Linssen; Helke A van Dessel; Dennis C J J Bergmans; Paul H M Savelkoul; Paul M H J Roekaerts; Walther N K A van Mook
Journal:  BMC Pulm Med       Date:  2015-08-12       Impact factor: 3.317

Review 8.  The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

Authors:  Jonathan S Boomer; Jonathan M Green; Richard S Hotchkiss
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

9.  Towards personalized medicine in sepsis: Quest for Shangri-La?

Authors:  Ayan Sen; Sachin Yende
Journal:  Crit Care       Date:  2013-02-11       Impact factor: 9.097

Review 10.  Therapeutic Boosting of the Immune Response: Turning to CD14 for Help.

Authors:  Anne-Catherine Raby; Mario O Labéta
Journal:  Curr Pharm Biotechnol       Date:  2016       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.